Get informed when a big investor buys or sells
+ FollowOvervalued by 134.3% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $349.25 Million |
|---|---|
| Enterprise Value | $500.49 Million |
| Earnings per Share | $-0.7 |
| Beta | 3.06 |
| Outstanding Shares | 100,647,451 |
| P/E Ratio | -1.78 |
|---|---|
| PEG | 0.02 |
| Price to Sales | - |
| Price to Book Ratio | -3.47 |
| Enterprise Value to Revenue | 19.88 |
| Enterprise Value to EBIT | -4.49 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.36 |
| Debt to Equity | -10.18 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to dis...